8-K: Sonendo to Acquire Biolase's Dental Laser Assets in Bankruptcy Deal

Sonendo, Inc. has entered into an asset purchase agreement to acquire certain assets of Biolase, Inc. and its subsidiaries related to dental laser systems for $14 million in cash, assumption of liabilities, and the value of a pending litigation.

Summary

• Sonendo, Inc. has agreed to acquire assets related to dental laser systems from Biolase, Inc. and its subsidiaries for a total purchase price of $14 million in cash, subject to a working capital adjustment, plus the assumption of certain liabilities and the value of a pending litigation.
• The deal includes specified inventory, intellectual property, products, contracts, equipment, and other intangibles related to the dental laser business.
• Sonendo will deposit 10% of the purchase price into escrow, which may be returned if the agreement is terminated due to certain events.
• Biolase and its subsidiaries have filed for Chapter 11 bankruptcy, and Sonendo will be the stalking horse bidder in a court-supervised sale process.
• The transaction is subject to higher bids at auction, bankruptcy court approval, and other customary conditions.
• If Biolase sells the assets to a competing bidder, Sonendo may receive a break-up fee equal to 3% of the purchase price plus capped expense reimbursement.
• Sonendo has also filed a proof of claim for $59 million against Biolase for alleged patent infringement related to laser systems and radial firing tips.

Sentiment

Score: 6

Explanation: The document presents a strategic acquisition opportunity but is tempered by the risks associated with a bankruptcy sale and potential competing bids. The patent claim adds another layer of uncertainty. The sentiment is cautiously optimistic.

Positives

• Sonendo secures a potential acquisition of valuable dental laser assets.
• The stalking horse bid provides a degree of protection and potential compensation if the deal does not proceed.
• The acquisition could expand Sonendo's product portfolio and market presence.
• The break-up fee and expense reimbursement offer some financial protection if the deal is outbid.

Negatives

• The deal is subject to a bankruptcy court-supervised auction, meaning Sonendo may not ultimately acquire the assets.
• There is a risk of higher bids from competing bidders.
• The transaction is subject to customary conditions and may not be completed.
• The outcome of the patent infringement claim against Biolase is uncertain.

Risks

• The acquisition is not guaranteed due to the bankruptcy auction process.
• Competing bids could result in Sonendo losing the assets or having to increase its offer.
• The integration of the acquired assets and liabilities could be challenging.
• The patent infringement claim against Biolase may not be successful.
• The transaction may be more expensive to complete than anticipated.
• There is a risk of business disruption and adverse effects on employee retention.

Future Outlook

The document outlines a potential acquisition, but the outcome is uncertain due to the bankruptcy process and potential competing bids. The company can give no assurances of the outcome of the Transaction and whether the Company will be successful in acquiring the Assets pursuant to the Asset Purchase Agreement.

Industry Context

This announcement reflects a strategic move by Sonendo to expand its presence in the dental laser market through acquisition. The bankruptcy of Biolase presents an opportunity for Sonendo to acquire assets at a potentially favorable price, but also introduces risks associated with the auction process and integration.

Comparison to Industry Standards

• The acquisition of assets out of bankruptcy is a common strategy for companies looking to expand or acquire technology at a discount.
• The use of a stalking horse bid is a standard practice in bankruptcy sales, providing an initial offer and setting a floor for the auction.
• The 3% break-up fee is within the typical range for such transactions, offering some compensation to the stalking horse bidder if outbid.
• The $59 million patent infringement claim is significant and could impact the overall value of the transaction and the future relationship between the companies.

Legal Proceedings

• Biolase and its subsidiaries have filed for Chapter 11 bankruptcy.
• Sonendo and PIPStek have filed a proof of claim for $59 million against Biolase for alleged patent infringement.

Stakeholder Impact

• Shareholders of Sonendo may see potential long-term value creation from the acquisition.
• Employees of Biolase may be affected by the bankruptcy and potential acquisition.
• Customers of Biolase may experience changes in product availability and support.
• Suppliers of Biolase may be impacted by the bankruptcy and potential acquisition.

Next Steps

• Sonendo will participate in the bankruptcy court-supervised auction process.
• The bankruptcy court will need to approve the asset purchase agreement and the sale.
• Sonendo will need to complete due diligence and finalize the transaction.
• Sonendo will need to integrate the acquired assets and liabilities if the deal is successful.

Key Dates

Keywords

dental laser systems, asset acquisition, bankruptcy, stalking horse bidder, intellectual property, patent infringement, medical devices, Biolase, Sonendo